Equity
€959,997 from €1.8m in 2020
Equity fell by 46% in 5 years.
MED.OPHTA
Lifetime
20 annual accounts with figures on one time axis, 27 filings since 1999peak €981,116 (2019)
€610,953▲ 9.2%
lowest -€3,973 (2022)
€396,563▲ 12.5%
peak €1.8m (2020)
€959,997▲ 44.2%
€416,405▼ 46.2%
peak 4.1 FTE (2020)
-not published
Board1 name since 2021
1 directorJean ASSAF
Documentsfilings and deeds
19-08-202619 days late
2025abbreviated format
Dividend €102,332Equity from €665,765 to €959,997Debts from €774,540 to €416,405Cash from €388,090 to €540,208
Key points
from the 2025 annual accountsFilings
27 annual accounts since 1999
Seven of the last ten came late. The 2019 accounts came latest: 48 days after the end of the period.
Position in the sector
€396,563
Higher net result than 92% of companies in real estate. Sector median €9,997 · 11,290 companies.
Checked score
98
Excellent
Financially stronger than 83% of micro companies in real estate (NACE 68)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 26,625 companies (NACE 68, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.2%▲ +0.1 percentage points vs 01-2025
03-2025: 0.2%● unchanged vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025highest value
08-2025: < 0.1%▼ -0.2 percentage points vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: 0.1%▲ +0.1 percentage points vs 07-2026
09-2026: < 0.1%▼ -0.1 percentage points vs 08-2026lowest value
10-2026: < 0.1%● unchanged vs 09-2026lowest value
11-2026: < 0.1%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
lowers risk
Liquidity: current ratio 2.46, cash €540,208
Size: turnover €0, total assets €1.7m
Equity €959,997 (57.2% of total assets)
Figures for financial year 2025 (filed on 21-08-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 68, micro). It does better than 69% of them on solvency, 90% on liquidity, 90% on profitability and 85% on growth.
The bankruptcy probability was computed on 07-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 20,137 companies had the same profile as MED.OPHTA has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
That fits the bankruptcy probability of MED.OPHTA itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,137 companies, not a prediction for MED.OPHTA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €90,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 2.46 (1.69 in 2024), above the usual 1.5. Short-term debt is 15.4% and cash 32.2% of total assets. 42.8% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
18192022232425
2018 to 2025 · latest year €959,997
raises risk · 2025 accounts filed 19 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 19-08-2026, 19 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
19 days late
2024
9 days early
2023
27 days late
2022
29 days late
2021
30 days late
2020
33 days early
2019
48 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 16 days after the deadline. In the sector (NACE 68), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
08-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Demerger: MED.OPHTA splits off to MO ACTIVITIES
Appointment: Jean ASSAF (director) · “Toutes opération et toutes études ayant trait à tous biens et/ou droits réels immobiliers, par nature, par…” (deed in French) · General meeting of 28-06-2021 · Gazette deed
Demerger proposal: MED.OPHTA splits off to MO Activities
Jean ASSAF holds 750 shares (100%) · Board meeting of 07-05-2021 · Gazette deed
Incorporation
published on 02-03-1999 · Gazette deed
First establishment
Brussels Eye Center, Papenkasteelstraat 33, Uccle
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MED.OPHTA Uccle | €1.7m | €0.6m | 57.2% | - |
| IMMO DIEST Diest | €1.8m | €0.6m | 42.6% | 5.8 |
| MINFOS Schilde | €1.6m | €0.5m | 79.9% | - |
| ALMIVER BRUGGE Roeselare | €1.7m | €0.5m | 86.0% | - |
| BOOMSE MINERAALBREKERIJ Uccle | €1.4m | €0.4m | 59.3% | - |
| C. DESSEILLE Uccle | €1.6m | €1.1m | 94.2% | - |
| VANDE Brussels | €2.1m | €0.4m | 41.1% | - |
These companies have the same main activity as MED.OPHTA: buying and selling of own real estate (NACE 68110). They are comparable in size and age: total assets between €1.4m and €2.1m, founded between 1993 and 2003.
Official details
Source: KBO- Status
- Active since 19-02-1999Normal situation
- Activity
- Buying and selling of own real estateNACE 68110
- Establishment unit
- 2.231.198.2551180 Uccle, since 18-02-1999
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Insights on MED.OPHTA
MED.OPHTA files the abbreviated format. That format states no turnover. The gross margin rose from €360,904 in 2006 to €610,953 in 2025.
The balance sheet grew most from 2017 to 2018 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MED.OPHTA
- What is the company number of MED.OPHTA?
- The company number of MED.OPHTA is 0465.485.974. The VAT number is the same number with BE in front: BE 0465.485.974.
- Where is MED.OPHTA based?
- The registered office is at Papenkasteelstraat 33, 1180 Uccle.Company details
- What does MED.OPHTA do?
- According to the KBO register, the main activity is buying and selling of own real estate (NACE 68110).
- What is the legal form of MED.OPHTA?
- MED.OPHTA is a private limited company (pre-2019) (BVBA).
- When was MED.OPHTA founded?
- MED.OPHTA was founded on 19-02-1999.
- Is MED.OPHTA still active?
- Yes, MED.OPHTA is an active enterprise in the KBO register.
- How many employees does MED.OPHTA have?
- MED.OPHTA had an average of 4.1 full-time equivalents in financial year 2020, according to the filed annual accounts.Financials
- What is the turnover of MED.OPHTA?
- The turnover of MED.OPHTA was €0 in financial year 2025, according to the filed annual accounts.
- Is MED.OPHTA profitable?
- In financial year 2025, MED.OPHTA made a profit of €396,563.
- Where can I find the annual accounts of MED.OPHTA?
- MED.OPHTA filed 27 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MED.OPHTA due?
- MED.OPHTA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.